89bio Inc (ETNB)

$8

-0.35

(-4.19%)▲

Live

Performance

  • $7.99
    $8.31
    $8.00
    downward going graph

    0.12%

    Downside

    Day's Volatility :3.85%

    Upside

    3.73%

    downward going graph
  • $6.58
    $16.63
    $8.00
    downward going graph

    17.81%

    Downside

    52 Weeks Volatility :60.46%

    Upside

    51.89%

    downward going graph

Returns

Period89bio IncSector (Health Care)Index (Russel 2000)
3 Months
0.48%
3.6%
0.0%
6 Months
-10.31%
10.2%
0.0%
1 Year
25.38%
19.6%
0.0%
3 Years
-52.29%
16.8%
-23.0%

Highlights

Market Capitalization
869.5M
Book Value
$4.91
Earnings Per Share (EPS)
-1.96
Wall Street Target Price
30.63
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-22.25%
Return On Equity TTM
-36.5%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-191.2M
Diluted Eps TTM
-1.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.28
EPS Estimate Next Year
-2.57
EPS Estimate Current Quarter
-0.57
EPS Estimate Next Quarter
-0.67

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for 89bio Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 282.88%

Current $8.00
Target $30.63

Technicals Summary

Sell

Neutral

Buy

89bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
89bio Inc
89bio Inc
8.87%
-10.31%
25.38%
-52.29%
-59.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
89bio Inc
89bio Inc
NA
NA
NA
-2.28
-0.36
-0.22
NA
4.91
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
89bio Inc
89bio Inc
Buy
$869.5M
-59.86%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on 89bio Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 60.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 97.1%

Institutional Holdings

  • RA Capital Management, LLC

    13.51%

  • HHG PLC

    12.65%

  • Suvretta Capital Management, LLC

    7.66%

  • Bvf Inc

    7.21%

  • RTW INVESTMENTS, LLC

    7.03%

  • BlackRock Inc

    6.69%

Company Information

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.

Organization
89bio Inc
Employees
70
CEO
Mr. Rohan Palekar
Industry
Health Technology

Discover More

FAQs